<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03817411</url>
  </required_header>
  <id_info>
    <org_study_id>EOC315B2101</org_study_id>
    <nct_id>NCT03817411</nct_id>
  </id_info>
  <brief_title>Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer</brief_title>
  <official_title>A Phase II Randomized Trial of Telatinib in Combination With Capecitabine/Oxaliplatin Versus Capecitabine/Oxaliplatin as First-Line Therapy in Patients With HER2-negative Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taizhou EOC Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai East Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Taizhou EOC Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to compare the combination regimen of Telatinib and Capecitabine&#xD;
      and Oxaliplatin vs. Capecitabine and Oxaplatin to explore superiority of the Telatinib&#xD;
      combination in terms of progression-free survival (PFS) in patients previously untreated for&#xD;
      advanced HER2 negative advanced gastric or Gastroesophageal Junction adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a Phase 2, prospective, double-blind, randomized, comparative, multicenter&#xD;
      trial in patients with advanced HER2 negative adenocarcinoma of the stomach or&#xD;
      Gastroesophageal Junction which has progressed after resection and adjuvant or neoadjuvant&#xD;
      therapy, or is unresectable or metastatic at time of first diagnosis. a total of&#xD;
      approximately 90 patients will be enrolled and randomized into Telatinib combined with&#xD;
      Capecitabine and Oxaliplatin or chemotherapy combined with placebo. All patients will be&#xD;
      treated until progressive disease (radiologically documented or symptomatic deterioration) or&#xD;
      the occurrence of unacceptable toxicity, withdrawal of consent or investigator's judgment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 25, 2019</start_date>
  <completion_date type="Anticipated">January 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>24 months</time_frame>
    <description>the proportion of patients with complete response (CR) or partial response (PR) among all patients assessed per RESIST v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>24 months</time_frame>
    <description>Progression free survival of All the Evaluable Participants.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as at least a 20% increase in the sum of diameters of target lesions, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CBR</measure>
    <time_frame>24 months</time_frame>
    <description>Clinical Benefit Rate, defined as CR+PR+SD≥ 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>24 months</time_frame>
    <description>the proportion of patients who had a best response rating of complete response, partial response, or stable disease</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Telatinib+Capecitabine+Oxaliplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive Telatinib orally (PO) twice daily (bid) on days 1-21 and Capecitabine PO on days 1-14, then stopped for 7 days, and Oxaliplatin by intravenous injection on day 1 of every cycle. Courses repeat every 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebos+Capecitabine+Oxaliplatin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo orally (PO) twice daily (bid) on days 1-21 and Capecitabine PO on days 1-14, then stopped for 7 days, and Oxaliplatin by intravenous injection on day 1 of every cycle. Courses repeat every 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telatinib</intervention_name>
    <description>300 mg tablets, 900 mg twice daily (BID) at 12h-intervals.</description>
    <arm_group_label>Telatinib+Capecitabine+Oxaliplatin</arm_group_label>
    <other_name>EOC315</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1000 mg/m²,twice daily for 14 days followed by a 7-day rest period (14 days on/7 days off schedule).</description>
    <arm_group_label>Placebos+Capecitabine+Oxaliplatin</arm_group_label>
    <arm_group_label>Telatinib+Capecitabine+Oxaliplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>130 mg/m2, administered intravenously over 2 hours, on Day 1 every 3 weeks (one administration per cycle) for a maximum of 6 cycles.</description>
    <arm_group_label>Placebos+Capecitabine+Oxaliplatin</arm_group_label>
    <arm_group_label>Telatinib+Capecitabine+Oxaliplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>300 mg tablets, 900 mg twice daily (BID) at 12h-intervals.</description>
    <arm_group_label>Placebos+Capecitabine+Oxaliplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female at least 18 and &lt;75 years old at the time of screening.&#xD;
&#xD;
          2. Histologically or cytologically confirmed unresectable locally advanced or metastatic&#xD;
             HER2 negative (or HER2 status unknown), gastric or gastro-oesophageal junction&#xD;
             adenocarcinoma.&#xD;
&#xD;
          3. Measurable or evaluable lesion as defined by RECIST v1.1.&#xD;
&#xD;
          4. No prior treatment for advanced disease. Adjuvant or neoadjuvant chemotherapy must be&#xD;
             stopped at least for 6 months.&#xD;
&#xD;
          5. Prior surgery and/or radiotherapy stopped for at least 4 weeks.&#xD;
&#xD;
          6. ECOG Performance Status 0-1.&#xD;
&#xD;
          7. Life expectancy of at least 3 months.&#xD;
&#xD;
          8. Adequate bone marrow function as evidenced by meeting all of the following&#xD;
             requirements:&#xD;
&#xD;
               1. Absolute neutrophil count &gt; 1.5 × 10 E+9/L without the use of hematopoietic&#xD;
                  growth factors&#xD;
&#xD;
               2. Platelet count &gt; 90 ×10 E+9/L without the need for transfusion in the 2 weeks&#xD;
                  prior the first dose&#xD;
&#xD;
               3. Hemoglobin &gt;90 g/L without the need for transfusion in the 2 weeks prior the&#xD;
                  first dose&#xD;
&#xD;
          9. Adequate hepatic function as evidenced by meeting all of the following requirements:&#xD;
&#xD;
               1. Serum total bilirubin ≤1.5 x upper limit of normal (ULN) (biliary drainage is&#xD;
                  allowed for biliary obstruction)&#xD;
&#xD;
               2. Serum albumin levels ≥3.0 g/dL&#xD;
&#xD;
               3. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) and and&#xD;
                  alkaline phosphatase (ALP): ≤3.0 x upper limit of normal (ULN) (≤5 x ULN if liver&#xD;
                  metastases are present and if liver and/or bone metastases ALP ≤ 5 × ULN.)&#xD;
&#xD;
         10. Adequate renal function as evidenced by&#xD;
&#xD;
               1. serum creatinine ≤1.5 x ULN and creatinine clearance of ≥50 mL/min&#xD;
                  (Cockcroft-Gault formula).&#xD;
&#xD;
               2. Urine dipstick for proteinuria of less than 2+ (other ways of urinalysis are also&#xD;
                  acceptable); if urine dipstick is ≥ 2+, proteinuria must be &lt; 2 g in 24 hours.&#xD;
&#xD;
         11. Prothrombin time (PT) or activated partial thromboplastin time (APTT) and&#xD;
             International Normalized Ratio (INR) ≤1.5 x ULN.&#xD;
&#xD;
         12. Recovered from the effects of any prior surgery, radiotherapy or other anti-neoplastic&#xD;
             adjuvant therapy. Unresolved toxicity &gt; Grade 1 (except alopecia) from previous&#xD;
             anticancer therapy (including radiotherapy) is accepted&#xD;
&#xD;
         13. If female of childbearing potential, the patient must present with a negative urine&#xD;
             pregnancy test and agrees to employ adequate birth control measures for at least 90&#xD;
             days after the duration of the study&#xD;
&#xD;
         14. Male who are not sterile agrees to take effective contraception for at least 90 days&#xD;
             after the last dose of drug and avoid donating sperm at the same time period.&#xD;
&#xD;
         15. Ability to swallow pills and no major intestinal surgery.&#xD;
&#xD;
         16. Able to understand and sign an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypertension and unable to be controlled within normal level following treatment of&#xD;
             anti-hypertension agents (systolic blood pressure &gt; 150 mmHg, diastolic blood pressure&#xD;
             &gt; 100 mmHg).&#xD;
&#xD;
          2. Active and uncontrolled central nervous system (CNS) metastases .&#xD;
&#xD;
          3. During the screening and study period, standard dose of anticoagulant or thrombolytic&#xD;
             drugs are used for treatment;&#xD;
&#xD;
          4. History of any second malignancy in the last 5 years; patients with prior history of&#xD;
             in-situ cancer or basal or squamous cell skin cancer are eligible. Patients with other&#xD;
             malignancies are eligible if they have been continuously disease free for at least 5&#xD;
             years.&#xD;
&#xD;
          5. Evidence of tumor invasion of major blood vessels by images(including complete&#xD;
             proximity, surrounding or extending into the main vascular lumen, such as the&#xD;
             pulmonary artery or the superior vena cava), and the investigator judged that it was&#xD;
             not suitable for enrollment.&#xD;
&#xD;
          6. A significant thrombotic or hemorrhagic event ≤ 6 months prior to Screening (includes&#xD;
             hemoptysis, gastrointestinal bleeding, hematemesis, CNS hemorrhage, severe epistaxis&#xD;
             or vaginal bleeding, cerebral infarction, transient ischemic attacks, myocardial&#xD;
             infarction, angina, and uncontrolled coronary artery disease).&#xD;
&#xD;
          7. History of active gastroduodenal ulcer, abdominal fistula as well as&#xD;
             nongastrointestinal fistula, gastrointestinal perforation or intraabdominal abscess&#xD;
             within 6 months prior to screening.&#xD;
&#xD;
          8. Significant cardiac conduction abnormalities, including a history of long QTc syndrome&#xD;
             and/or pacemaker.New York Heart Association Class III or IV congestive heart failure,&#xD;
             ventricular arrhythmias&#xD;
&#xD;
          9. Exposure to any other investigational or commercial anticancer agents or therapies&#xD;
             (Chinese herbal medicines e.g) administered with the intention to treat malignancy&#xD;
             within 28 days.&#xD;
&#xD;
         10. Active infection or an unexplained fever during screening visits or on the first&#xD;
             scheduled day of dosing (at the discretion of the Investigator, patients with tumor&#xD;
             fever may be enrolled), which in the investigator's opinion might compromise the&#xD;
             patient's participation in the trial or affect the trial outcome.&#xD;
&#xD;
         11. Positive test or known history of for human immunodeficiency virus (HIV), active&#xD;
             hepatitis B (HBsAg) or hepatitis C (anti-HCV antibody) or syphilis (syphilis antibody)&#xD;
&#xD;
         12. If female, the patient is pregnant or lactating at the time of enrollment.&#xD;
&#xD;
         13. Known hypersensitivity to any of the components of fluoropyrimidines or platinum&#xD;
             cmpounds.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Li, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Easter Hospital, Dpt. of Clinical Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tian Shu Liu, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Fudan Zhongshan Hospital, Dpt. of Clinical Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peng Wang, M.S.</last_name>
    <phone>18606193900</phone>
    <email>peng.wang@eocpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jie Li, M.S.</last_name>
    <phone>18951813306</phone>
    <email>jie.li@eocpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Easter Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Li, M.D.</last_name>
      <phone>021-20334612</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 24, 2019</study_first_submitted>
  <study_first_submitted_qc>January 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2019</study_first_posted>
  <last_update_submitted>May 3, 2019</last_update_submitted>
  <last_update_submitted_qc>May 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

